MCL1 and melanoma: Aside from KRAS (colorectal cancer, amplified in 1% of TCGA cases), MCL1 (lung squamous carcinoma, 4.7%) and BRAF (melanoma, 4.1%) amplifications have also been implicated as oncogenic alterations in OncoKB (43).